<DOC>
	<DOCNO>NCT01826370</DOCNO>
	<brief_summary>This prospective , non-interventional , open label , multi center , post marketing surveillance study design assess safety , tolerability efficacy Linagliptin among Filipino patient type 2 Diabetes Mellitus ( DM ) within study duration 24 week .</brief_summary>
	<brief_title>Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Filipino Asian race 2 . Patient use Linagliptin within label locally approve indication . The prescription Linagliptin patient must course normal clinical practice independent decision include patient study . 3 . Male female patient 18 year old 4 . Body mass index less equal 40 5 . Diagnosed type 2 DM 6 . Uncontrolled type 2 DM fast blood sugar 126 mg/dl and/or HbA1c 7 % . Exclusion criterion : 1 . Diagnosed type 1 DM 2 . Patients acute illness require hospitalization past one month 3 . Patients participate different study include investigational drug 4 . Patients know hypersensitivity reaction Linagliptin ti component 5 . Pregnant woman woman intention get pregnant within study duration 6 . Nursing woman 7 . Patients concomitant condition contraindicates Linagliptin use describe product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>